CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025Recent strategic in-license of TPI 287 is highly synergistic with the ongoing potentially pivotal Berubicin …
Jetzt den vollständigen Artikel lesen